FMD and PWV of patients with diabetes with (T2DM-SCT) or without (T2DM) SCT and of healthy individuals with (SCT) or without (CONT) SCT. FMD measured at.

Slides:

Advertisements

Similar presentations

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Advertisements

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

Engagement in recommended behaviors to prevent type 2 Diabetes (n=82)

Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.

Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

Demonstrating changes in brachial artery diameter, with FMD transient response following cuff deflation at 5 min (frame ∼1800) and sustained NMD response.

Comparison of clinical and functional parameters between the CMV+ and CMV− participants in the healthy elderly and elderly patients with T2DM. Comparison.

The results of the influenza vaccination measured by hemagglutination inhibition assay (HIA) among healthy elderly and elderly patients with type 2 diabetes.

X-bar and S control charts of LOS

Age, cytomegalovirus (CMV) seropositivity in the healthy and type 2 diabetes mellitus (T2DM) and the response to influenza vaccination after the CMV serostatus.

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

Trends in prevalence of diabetes in middle-aged women grouped according to BMI at the first survey of the ALSWH. ▪, healthy (n = 5,252); ♦, overweight.

A: PPG increment at week 26 for mealtime faster aspart versus IAsp.

Involvement of IRS-1 in L-783,281–stimulated increases in [Ca2+]i and exocytosis. Involvement of IRS-1 in L-783,281–stimulated increases in [Ca2+]i and.

Age-adjusted OR (A) and multivariate-adjusted OR (B) and 95% CI for the presence of retinopathy and albuminuria by quintiles of WBC count in 3,776 patients.

An algorithm depicting the basic approach to the Charcot foot

Mean mesangial area (micron2) across normal controls (normal C), patients with type 2 diabetes and normoalbuminuria (normo), patients with type 2 diabetes.

The incidence of insulin-treated type 1 diabetes in the first 35 years of life. The incidence of insulin-treated type 1 diabetes in the first 35 years.

Plasma angiopoietin-like protein 4 (ANGPTL4) in healthy controls (Controls), patients with metabolic syndrome without (MetS−I) and with low-grade inflammation.

Prevalence of high SAT or high VAT by BMI category in women (A) and men (B) and by waist circumference category in women (C) and men (D). Prevalence of.

A: Insulin-stimulated total, oxidative, and nonoxidative glucose disposal in subjects with NGT (open bars), IFG (dotted bars), IGT (striped bar), IFG/IGT.

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

HRs for prostate cancer by medication status.

Forefoot peak plantar pressure in diabetic patients without and with mild, moderate, and severe peripheral neuropathy. *Severe and moderate neuropathy.

The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.

A: The correlation between the GIR and FGU, each measured during the last 40 min of the euglycemic insulin clamp. A: The correlation between the GIR and.

Pooled risk with 95% CI of ACM (A) and CVD risk (B) for the highest vs

The effect of PAD and infection on outcome of cast treatment

Kaplan-Meier estimation of diabetes-related survival curves in patients grouped according to increased 24-h proteinuria (A), the presence of preexisting.

Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.

Two-year changes in albumin-to-creatinine ratio across microalbuminuria at baseline. Two-year changes in albumin-to-creatinine ratio across microalbuminuria.

Effect of age, sex, race/ethnicity, and obesity on the relation of glycemic measures to Si and AIR. In linear regression models with Si as the dependent.

Forest plot and pooled estimates of the effect of NAFLD on the risk of incident diabetes in 16 eligible studies, stratified by length of follow-up (FU)

Relationship between week 24 A1C and week 24 BeAM in the exploratory analysis (A), the main analysis (only patients with A1C >7.0% at week 24 were included.

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Waveform analysis at the popliteal artery in 176 diabetic patients with normal ABI (non-PAD). Waveform analysis at the popliteal artery in 176 diabetic.

A total of 173 individuals were positive for GADA, and 16 of these were positive for a second antibody (11 were IA-2A positive, and 6 were ZnT8A positive).

Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Study design (A) and patient disposition (B).

Median (interquartile range) of sensor glucose (A) and insulin delivery (B) during closed-loop (solid red line and red shaded area) and control period.

Pooled analysis of association between (nonexclusive) breast-feeding and childhood-onset type 1 diabetes in studies investigating ∼2 weeks (nonexclusive)

Percent binding of cross-reactive antibodies from cross-over studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

RBP4 and glucose metabolism.

Percent binding of cross-reactive antibodies from parallel studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

Box-and-whisker plots of SMAP assessed by AUC in diabetic patients with normoalbuminuria and albuminuria, treated with or without aspirin. Box-and-whisker.

Visualization of prescriptive algorithm: provider dashboard prototype.

Periods of activation for the knee extensor (VL) and ankle extensor (GN) muscles with respect to foot-step contact (occurring at time zero) during stair.

A: Typical course of a normal sympathetic vasomotor response as recorded by continuous wave Doppler sonography. A: Typical course of a normal sympathetic.

Plots of average estimated and measured GFR vs

Doses of trial medication in the liraglutide groups (A) and in the placebo groups (B). Doses of trial medication in the liraglutide groups (A) and in the.

Mean HbA1c (%) and estimated marginal mean SH rate (per 100 patient-years) adjusted for sex, age-group at diagnosis, and diabetes duration, by time period,

Pooled estimate of relative risk and 95% CIs of colorectal cancer associated with metformin therapy based on four studies comprising 107,961 diabetic patients.

Correlation between urinary albumin excretion rate and expression of platelet surface markers, active GPIIb/IIIa, and P-selectin. Correlation between urinary.

Incidences of transitions between glycemic states by 25-OHD level.

A1C at baseline, 16 weeks, and 32 weeks according to study group in all participants (A), adult participants (B), and adolescent participants (C) who returned.

Changes in autoantibody titers and GADA IgG1–4 subclass distribution.

The prevalence of cerebral infarction in the subjects with zero to seven proatherothrombotic alleles. The prevalence of cerebral infarction in the subjects.

Effects of metformin on GLP-1(7–36)amide degradation in vitro shown by GLP-1(7–36)amide concentrations (% variation from time 0) after a 30-min incubation.

Differences in the values of HbA1c variables between the retinopathy-positive and retinopathy-negative groups at year 20. Differences in the values of.

Complex association between Hb level and GFR, sex, and AER

Upper panel: For performance of the 10-g monofilament test, the device is placed perpendicular to the skin, with pressure applied until the monofilament.

GDF-15 levels in progressors and nonprogressors in albuminuria (case and control subjects) for patients with T2DM and nondiabetic patients with HT. A:

Manhattan plot of 11,628 m/z features comparing participants who developed incident T2D versus those who did not. Manhattan plot of 11,628 m/z features.

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

Change in first-phase insulin response (A) and pancreas triglyceride content (B) in responders and nonresponders at baseline (hatched bars), after VLCD.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Insulin secretion (hyperglycemic clamp) (A), insulin sensitivity (hyperinsulinemic-euglycemic clamp) (B), and glucose disposition index (GDI) (C) in adolescents.

Presentation transcript:

FMD and PWV of patients with diabetes with (T2DM-SCT) or without (T2DM) SCT and of healthy individuals with (SCT) or without (CONT) SCT. FMD measured at 90 s (A), FMD measured at 90 s corrected by shear stress values (B), mean FMD determined over 10 min after cuff deflation (C), and PWV (D) in the different groups. FMD and PWV of patients with diabetes with (T2DM-SCT) or without (T2DM) SCT and of healthy individuals with (SCT) or without (CONT) SCT. FMD measured at 90 s (A), FMD measured at 90 s corrected by shear stress values (B), mean FMD determined over 10 min after cuff deflation (C), and PWV (D) in the different groups. The two extremities of the horizontal bars indicate the difference between two given groups (*P < 0.05; ***P < 0.001). Means ± SD. Mor Diaw et al. Dia Care 2015;38:2120-2127 ©2015 by American Diabetes Association